Results 231 to 240 of about 67,846 (274)
Some of the next articles are maybe not open access.
Pediatric Annals, 1989
Twelve children with myasthenic symptoms were seen over a period of 6 years. The age of onset of symptoms ranged from 6 months to 9 years. On followup for a mean period of 4.25 years, (longest followup was 9 years) five children went into complete remission of symptoms after treatment with prostigmine; three children responded to prostigmine and ...
openaire +4 more sources
Twelve children with myasthenic symptoms were seen over a period of 6 years. The age of onset of symptoms ranged from 6 months to 9 years. On followup for a mean period of 4.25 years, (longest followup was 9 years) five children went into complete remission of symptoms after treatment with prostigmine; three children responded to prostigmine and ...
openaire +4 more sources
Disease-a-Month, 1997
Adult-onset myasthenia gravis is an acquired autoimmune disorder of neuromuscular transmission in which acetylcholine receptor antibodies attack the postsynaptic membrane of the neuromuscular junction. Although the cause of this disease is unknown, the role of immune responses in its pathogenesis is well established.
openaire +2 more sources
Adult-onset myasthenia gravis is an acquired autoimmune disorder of neuromuscular transmission in which acetylcholine receptor antibodies attack the postsynaptic membrane of the neuromuscular junction. Although the cause of this disease is unknown, the role of immune responses in its pathogenesis is well established.
openaire +2 more sources
Current Treatment Options in Neurology, 2010
Treatment of patients with acquired (autoimmune) myasthenia gravis should rely on evidence-based therapeutic choices, taking into account the individual's needs according to disease severity (mild to severe), extent (ocular or generalized), comorbidities (including other autoimmune diseases, infections, thymoma, and pregnancy), age, iatrogenic factors (
Agnes, Jani-Acsadi, Robert P, Lisak
openaire +2 more sources
Treatment of patients with acquired (autoimmune) myasthenia gravis should rely on evidence-based therapeutic choices, taking into account the individual's needs according to disease severity (mild to severe), extent (ocular or generalized), comorbidities (including other autoimmune diseases, infections, thymoma, and pregnancy), age, iatrogenic factors (
Agnes, Jani-Acsadi, Robert P, Lisak
openaire +2 more sources
JAAPA
Myasthenia gravis (MG) is a rare neuromuscular junction disorder that is characterized by fatigable weakness of muscles. People with MG experience various clinical manifestations based on the muscles involved. MG can be autoimmune, paraneoplastic, congenital, medication-related, or transient in the neonatal period due to the passive placental transfer ...
Mamatha, Pasnoor +2 more
openaire +4 more sources
Myasthenia gravis (MG) is a rare neuromuscular junction disorder that is characterized by fatigable weakness of muscles. People with MG experience various clinical manifestations based on the muscles involved. MG can be autoimmune, paraneoplastic, congenital, medication-related, or transient in the neonatal period due to the passive placental transfer ...
Mamatha, Pasnoor +2 more
openaire +4 more sources
The Neurologist, 2002
In myasthenia gravis (MG), the prototypic autoimmune disease, antibodies against acetylcholine receptors impair neuromuscular transmission and produce weakness. Although recognized for several hundred years, it has only been over the last three decades that effective treatments have become available for MG.This review summarizes the principles of ...
openaire +2 more sources
In myasthenia gravis (MG), the prototypic autoimmune disease, antibodies against acetylcholine receptors impair neuromuscular transmission and produce weakness. Although recognized for several hundred years, it has only been over the last three decades that effective treatments have become available for MG.This review summarizes the principles of ...
openaire +2 more sources
Veterinary Clinics of North America: Small Animal Practice, 1979
Myasthenia gravis is characterized by muscle weakness, which is alleviated by rest and by anticholinesterase drugs. There are two forms of the disease in the dog, acquired and congenital. The acquired form occurs either in young adults, or in older animals that have developed mediastinal tumors. Clinically, there is weakness of the muscles of the limbs,
openaire +2 more sources
Myasthenia gravis is characterized by muscle weakness, which is alleviated by rest and by anticholinesterase drugs. There are two forms of the disease in the dog, acquired and congenital. The acquired form occurs either in young adults, or in older animals that have developed mediastinal tumors. Clinically, there is weakness of the muscles of the limbs,
openaire +2 more sources
Schweizer Archiv fur Neurologie, Neurochirurgie und Psychiatrie = Archives suisses de neurologie, neurochirurgie et de psychiatrie, 1983
A Central Nervous System (CNS) acetylcholine receptors involvement in Myasthenia Gravis (MG) has been suggested but never fully demonstrated. On the other hand, although the question concerning the neurotransmitters connected to REM sleep is still unsettled, the importance of acetylcholine as a neurotransmitter involved in the maintenance of this sleep
Mennuni, Gioacchino +8 more
openaire +2 more sources
A Central Nervous System (CNS) acetylcholine receptors involvement in Myasthenia Gravis (MG) has been suggested but never fully demonstrated. On the other hand, although the question concerning the neurotransmitters connected to REM sleep is still unsettled, the importance of acetylcholine as a neurotransmitter involved in the maintenance of this sleep
Mennuni, Gioacchino +8 more
openaire +2 more sources